Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760824 | 0.88 | AR (0.51) | AR | |
| SCHEMBL5865881 | 0.86 | AR (0.60) | AR | |
| SCHEMBL5761325 | 0.83 | AR (0.61) | AR | |
| SCHEMBL5761765 | 0.82 | AR (0.56) | AR | |
| SCHEMBL6094982 | 0.82 | AR (0.72) | AR | |
| SCHEMBL5859895 | 0.82 | AR (0.54) | AR | |
| SCHEMBL6106659 | 0.82 | AR (0.51) | AR | |
| SCHEMBL6108419 | 0.82 | AR (0.54) | AR | |
| SCHEMBL5757800 | 0.82 | AR (0.54) | AR | |
| SCHEMBL5759800 | 0.82 | HTT (0.50) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | disclosed |
| US-7057048-B2 | Androgen receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1633732-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1587509-A2 | ANDROGEN RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050085466-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | disclosed |
| WO-2004101544-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004065539-A2 | ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085466-A1 | Androgen receptor antagonists | AR, NR5A1, ESRRB | AR 1/4885 |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | AR, SHBG, BRDT | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.